TeVido’s therapy-as-a-service (TAAS) stands to address significant unmet needs in reconstructive and cosmetic surgery with autologous cell therapy for patients with vitiligo and nipple areola reconstruction for breast cancer survivors. Currently, vitiligo patients are unable to easily access the most effective treatment options and breast cancer survivors who choose to have reconstructive survey have limited options when it comes to the aesthetic outcome of their procedure. Our techniques in biofabrication and 3-D bioprinting support deposition of cells and biomaterials in precise locations, layer by layer, which results in a highly customizable product, improving outcomes and changing lives.
TeVido is a combination of two spanish words, tejido (tissue) and vida (life).
This is our mission
At TeVido BioDevices, we use a patient's own tissue to enhance the quality of their life.
For those interested in a technical overview, please Contact Us.
Laura Bosworth is CEO and co-founder of TeVido BioDevices. Ms. Bosworth is a dynamic former Fortune 50 executive with over 25 years of cross-functional industry experience. With over 18 years in product, process and service development at both the engineering and marketing level, she has experience launching new business start-ups within a larger corporation. She has led numerous successful strategy efforts.
With a B.S. in Metallurgical Engineering from the University of Texas at El Paso she started her career in manufacturing process development for IBM Austin. She quickly moved into management where she led custom software development projects and launched a Technical Marketing Center earning a General Manager’s Award for her contributions to sales. At Dell, she led organizations in building strategic business partnerships, software product marketing and created multiple technical sales support functions: enabling over $500M in sales. She launched a professional services business unit and has expertise in customer support services. Using her cross-functional and international experience, she developed corporate wide strategies that reduced operating costs by ~$120M and improved customer satisfaction by 40-50%.
Ms. Bosworth developed curricula, taught and provided mentorship with several applied entrepreneurship programs (EDCO Ventures, Texas State University and AVINDE) focused on mentoring aspiring underrepresented and women entrepreneurs , to develop their own high-growth (more than a $1 Million) companies. Ms. Bosworth has served on UTEP’s College of Engineering Advisory Board and in 2010, she led a task force that recommended a strategy to create a culture of innovation and entrepreneurship and is now involved in its implementation.
Ms. Bosworth has volunteered for numerous non-profits, primarily supporting women’s needs in the Science Technology Engineering and Math (STEM) field as well as domestic violence – in Board positions as well as providing direct service. She volunteers as a Spanish interpreter at a Healthcare Clinic that serves low-income individuals
Dr. Scott Collins, Chief Technology Officer and President of Research and Development at TeVido BioDevices, is an accomplished leader with 23 years expertise spanning engineering, the life sciences, biodevices, corporate strategy, operations, design, and consulting including 14 years of proven leadership experience spanning all aspects of forming, growing and selling a technology company.
At Arrhythmia Research Technology he led internal engineering development and designed a biological data acquisition system that analyzed electrophysiological signals in real time. The system was launched and used by cardiologists in the research market. Next, Collins designed a portable acquisition system that spanned the research and clinical markets, providing a way for clinicians to move their research to the bedside quicker in a way similar to what later became the iPhone / apps store in the consumer market.
Subsequently, Dr. Collins formed and grew a business in the IT space that advised companies on how to utilize technology effectively to meet business objectives. He successfully exited this business to pursue a PhD in Biomedical Engineering, where he set up two state of the art stem cell and tissue engineering labs, developed imaging protocols for complex 3D cell cultures and created or enhanced several protocols related to de novo microvascular channel formation--fundamental to the fields of tissue engineering and regenerative medicine.
Dr. Collins is on the Scientific Advisory Board for the New Organ Prize, an initiative of the Methuselah Foundation, a public charity dedicated to advancing and celebrating regenerative technologies to reduce unnecessary suffering and extend healthy life. He is a founding Board Member of BioAustin.
Dr. Thomas Boland, Chief Science Advisor and co-founder of TeVido BioDevices currently holds, in association with Clemson University, a US Patent with broad claims for inkjet tissue printing. Live-cell tissue printing has been his primary field of research for over 10 years, and he has received over $8M in research funding for his work. Dr. Boland’s work has been cited more than 800 times. He’s received numerous awards and was featured on CNN and the Discovery Channel for his groundbreaking research using inkjet printers to assemble cells and biomaterials into viable and functioning structures. Dr Boland is the Director of Biomedical Engineering at the University of Texas at El Paso (UTEP).
Francisco Agullo, M.D., is certified by the American Board of Plastic Surgery and the American Board of Surgery. He has joined El Paso Cosmetic Surgery as a plastic surgeon serving the cosmetic needs of West Texas, New Mexico, and Northern Mexico.
Dr. Frank Agullo graduated from the world-famous Mayo Clinic in Rochester, Minnesota, and he stays current in all of the latest aesthetic procedures and technologies. Dr. Agullo also holds the position of clinical assistant professor at Texas Tech University.
Elisa Maldonado-Holmertz has over 20 years experience in multinational pharma, life sciences and medical device industries. She has worked locally in both emerging and established markets (USA, Belgium, Sweden, P.R. China) spanning an array of indications including wound healing. Most relevant to TeVido, she has been integral to several start-ups. In addition to her industry background, she has graduate work in Business Management and Health Economics. Her experience in clinical research, reimbursement and market access, marketing and sales, and RA/QA are of tremendous value to TeVido. Ms. Maldonado-Holmertz has recently left her position as VP Business Development at Emergo Group to pursue consulting.